Yuanhui Zhang

Estimated Public Health Impact of the Recombinant Zoster Vaccine

J. Stoddard, B. Patterson, P. Buck, 2021, Mayo Clinic Proceedings: Innovations, Quality & Outcomes.

Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom

J. Lechner-Scott, M. Trojano, F. Grand'Maison, 2021, PharmacoEconomics.

Public health and economic impact of adjuvanted recombinant zoster vaccine adoption for a large, integrated delivery network: Utilizing real‐world epidemiological data in a budget impact model

B. Patterson, K. Bruxvoort, H. Tseng, 2019 .

Clinical and economic outcomes associated with respiratory syncytial virus vaccination in older adults in the United States.

V. Shinde, S. Talbird, B. Rosen, 2021, Vaccine.

Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model

B. Patterson, K. Bruxvoort, H. Tseng, 2020, Journal of managed care & specialty pharmacy.